Lexeo Therapeutics Inc SEC Filings

Lexeo Therapeutics (LXEO) filing Form 144 to notify a proposed sale of 1,115 common shares through Fidelity Brokerage Services on 08/18/2025. The shares were acquired on 08/15/2025 upon restricted stock vesting from the issuer and the consideration is listed as compensation. The filing reports an aggregate market value of $5,205.04 for the shares and shows 54,001,214 shares outstanding, indicating the sale represents a very small fraction of the outstanding common stock. The filer certifies under the form that they are not aware of undisclosed material adverse information about the issuer.

Lexeo Therapeutics (LXEO) reported a Form 144 notice for the proposed sale of 382 common shares, with an aggregate market value of $1,783.25, to be sold on 08/18/2025 on NASDAQ. The shares were acquired on 08/15/2025 through restricted stock vesting from the issuer and were paid as compensation. The filing shows 54,001,214 shares outstanding and notes no securities sold by the filer in the past three months. The notice includes the standard representation that the seller has no undisclosed material adverse information.

Form 144 filed for Lexeo Therapeutics, Inc. (LXEO) reports a proposed sale of 542 common shares, with an aggregate market value of $2,530.16, to be sold on 08/18/2025 on NASDAQ through Fidelity Brokerage Services LLC.

The shares were acquired on 08/15/2025 through restricted stock vesting from the issuer and payment/settlement is recorded as 08/15/2025. The filing shows 54,001,214 shares outstanding for the class and indicates no other sales in the past three months.

Citadel-linked entities disclose a substantial passive stake in Lexeo Therapeutics (LXEO). Collectively, Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC report beneficial ownership of 5,325,269 shares, representing 9.6% of outstanding shares on a fully calculated basis of 55,718,516 shares (including 1,717,302 shares issuable upon warrant conversion). Citadel Securities entities separately report 8,843 shares. Kenneth Griffin is reported to beneficially own 5,334,112 shares (also 9.6%). The filing states the positions were not acquired to change or influence control and identifies the reporting persons, organization structure and shared voting/dispositive powers.

Vestal Point Capital, LP and Ryan Wilder report beneficial ownership of 3,228,161 shares of Lexeo Therapeutics, Inc. (ticker LXEO), representing 6.0% of the outstanding common stock. The percentage is calculated using an aggregate share count of 53,987,117 shares, reflecting 33,196,997 shares reported as of May 9, 2025, plus 20,790,120 shares issued in a May 27, 2025 private placement. Vestal Point acts as investment manager to a fund and a managed account that hold the shares; Mr. Wilder is the investment manager’s CIO and managing partner and signed the filing. The filing states the shares were acquired and are held in the ordinary course of business and not to influence control.

This Schedule 13G/A reports the beneficial ownership positions of multiple Frazier Life Sciences entities in Lexeo Therapeutics, Inc. common stock and clarifies prior attributions. Frazier Life Sciences Public Fund, L.P. directly holds 3,073,467 shares and related entities hold additional positions including 624,804, 87,424, 232,784 and 406,246 shares across several affiliated funds, with individual percentages reported as high as 5.7% and others at 1.2%, 0.2%, 0.4% and 0.8% respectively.

The filing states these reported share amounts exclude certain warrants and discloses warrant ceilings: FLSPF holds warrants to purchase 2,647,440 shares; FLSPOF 781,005; FLS X 109,280; FLS XI 290,980; and FLS XII 507,809, each subject to a ~9.99% beneficial-ownership exercise limit. The statement explains shared voting and dispositive power structures through general partners and investment committees and corrects any prior over-attribution to individual committee members. The percentage calculations rely on the issuer's reported outstanding shares and shares sold in a public offering as set forth in the filing.

Janus Henderson Group plc disclosed a significant passive position in Lexeo Therapeutics, reporting beneficial ownership of 3,684,383 shares, representing 11.1% of the company's common stock. The filing shows shared voting and dispositive power over these shares rather than sole control, and the filer certifies the holdings are held in the ordinary course of business and not to change or influence control.

Separately, Janus Henderson Biotech Innovation Master Fund Ltd is reported to beneficially own 2,041,481 shares (about 6.2%) with shared voting and dispositive power. The filing includes a power of attorney authorizing Janus Henderson personnel to make required regulatory filings on behalf of the group.

Lexeo Therapeutics reported financial and clinical updates for the period ended June 30, 2025. The company holds approximately $152.5 million in cash, cash equivalents and U.S. Treasury securities and an accumulated deficit of $338.9 million. Net loss for the six months was $58.8 million, driven by total operating expenses of $64.5 million year-to-date, with general and administrative costs rising notably versus the prior year.

Liquidity was strengthened by a May 2025 private placement that raised gross proceeds of ~$80.0 million and net proceeds of $73.1 million, and management estimates current resources are sufficient to fund operations for at least 12 months. Clinically, Lexeo highlighted progress with LX2006 in Phase 1/2 and an investigator-initiated Cornell trial, reporting early improvements in cardiac biomarkers and measurable increases in cardiac frataxin protein in biopsies for some patients, generally well-tolerated aside from one transient Grade 2 asymptomatic myocarditis. The company has FDA alignment on a registrational plan using left ventricular mass index and frataxin protein expression as co-primary endpoints.

Lexeo Therapeutics announced a planned CFO transition: Louis Tamayo will become Chief Financial Officer effective August 15, 2025, succeeding Dr. Kyle Rasbach, who will provide transition support through August 29, 2025. Mr. Tamayo joins with senior finance experience at Siemens Healthineers, Becton Dickinson and Pfizer.

Mr. Tamayo's initial compensation includes a $480,000 base salary, a discretionary target cash bonus equal to 40% of base salary, 45,000 RSUs and options to purchase 280,000 shares with standard multi-year vesting. Termination protections provide a lump-sum payment equal to 12 months' base salary and up to 12 months of COBRA reimbursement; enhanced change-in-control provisions add a year’s target bonus, COBRA and equity acceleration. Dr. Rasbach will receive a $128,000 lump sum and accelerated vesting of 40,466 options, and his resignation was stated to not result from any disagreement with the company.